| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 103,335 | 72,820 | ||
| Short-term investments | 229,261 | 192,662 | ||
| Prepaid expenses and other current assets | 9,639 | 10,429 | ||
| Total current assets | 342,235 | 275,911 | ||
| Property and equipment, net | 489 | 569 | ||
| Operating lease right-of-use assets | 1,046 | 1,180 | ||
| Other assets | 361 | 367 | ||
| Long-term investments | 139,995 | 242,302 | ||
| Total assets | 484,126 | 520,329 | ||
| Accounts payable | 1,722 | 2,461 | ||
| Accrued expenses and other current liabilities | 29,847 | 24,203 | ||
| Operating lease liabilities, current | 1,188 | 1,394 | ||
| Total current liabilities | 32,757 | 28,058 | ||
| Operating lease liabilities, net of current portion | 0 | 125 | ||
| Total liabilities | 32,757 | 28,183 | ||
| Common stock, 0.0001 par value, 150,000,000 shares authorized as of september 30, 2025 and december 31, 2024 59,076,259 and 58,510,610 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 6 | 6 | ||
| Additional paid-in capital | 987,796 | 978,329 | ||
| Accumulated other comprehensive income (loss) | 973 | 607 | ||
| Accumulated deficit | -537,406 | -486,796 | ||
| Total cullinan stockholders' equity | 451,369 | 492,146 | ||
| Noncontrolling interests | 0 | 0 | ||
| Total stockholders' equity | 451,369 | 492,146 | ||
| Total liabilities and stockholders' equity | 484,126 | 520,329 | ||
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)